EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel By Ogkologos - August 26, 2025 362 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Today is Giving Tuesday December 1, 2020 Real-World Patients with Cancer Show Lower Survival Times and Treatment-Associated Survival... March 18, 2025 Man Gets His First Haircut In 15 Years To Join The... August 21, 2019 Stress-Induced Immune Changes May Help Cancer Spread April 2, 2024 Load more HOT NEWS The Childhood Cancer Data Initiative: Why Data Sharing Is Essential to... EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel Celebrate with Us! Vaccine Rollouts Mark the Light at the End... Two Years of Adjuvant Palbociclib Added to Endocrine Therapy Does Not...
